Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial

Sub-group analysis (n= 9983) ticagrelor plus aspirin showed similar efficacy and safety vs aspirin alone in patients presenting with moderate acute ischemic stroke and those presenting with less severe ischemic cerebrovascular events.

SPS commentary:

The observed primary outcome event rate, time to stroke or death within 30 days, in patients with moderate stroke was 7.6% in the ticagrelor group and 9.1% in the placebo group (HR, 0.84; 95% CI, 0.66-1.06). In patients with less severe stroke, the primary outcome event rate was 4.7% and 5.7%, respectively, (0.82; 0.66-1.01; P = 0.88).

JAMA Neurology